Centrillion Biosciences Receives Centrillion Biosciences Funding For Genomic Technology Development

PALO ALTO, Calif., April 17, 2015 /PRNewswire/ -- Centrillion Technologies, a genomic technologies company, has received a SBIR grant from the National Human Genome Research Institute, part of the National Institutes of Health (NIH). The grant will help fund the company's ongoing research efforts in the development of breakthrough genomic technologies, including phased sequencing of complete genomes using specially fabricated substrates. Centrillion has been developing this transformative and highly innovative technology to address the most significant challenges in genomics today.

Principal Investigator of this research project, Filip Crnogorac, Ph.D., Director of Advanced Technology at Centrillion, commented, "We are thrilled at the opportunity to incorporate the latest advances in semiconductor technology to develop a new generation of phased genome sequencing."

"We are grateful to the NIH for this support which will help accelerate the advancement of new genomic technologies and ultimately benefit life science research and patient care," said Wei Zhou, Ph.D., CEO at Centrillion.

Silicon Valley based Centrillion is creating transformative genomic technologies leveraging engineering and biochemistry breakthroughs to accelerate discovery and reveal the real genome that has thus far been obscured by its complexity and the limitations of existing technologies. Our team of scientists and engineers is committed to making a new generation of genomic technologies accessible and affordable for a multitude of previously unapproachable apps.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/centrillion-receives-nih-funding-for-genomic-technology-development-300067993.html

SOURCE Centrillion Technologies